In cholangiocarcinoma, FGFR2 fusions are generally mutually exclusive with alterations in MAPK pathway (KRAS, NRAS and BRAF) in baseline samples26, reflecting their roles as alternative oncogenic drivers. Here, NRAS is linked to cholangiocarcinoma.